Diagnosis Archives – Page 2 of 3 – Treatment Action Group

Time for $5 Coalition Statement: Cepheid’s Updated GeneXpert Pricing Does Not Address Country Needs

May 10, 2021
Dorrit Walsh

The Time for $5 Coalition, comprised of over 150 civil society organizations globally, calls out Cepheid for the company’s insufficient and self-serving GeneXpert pricing packages for low- and middle-income countries (LMICs), announced May 6, 2021.

Open Letter: Urgent Action Necessary to Improve Equitable Access to GeneXpert TB Diagnostics and Achieve 1/4/6×24

February 2, 2021
Dorrit Walsh

A coalition of civil society activists, including TAG, public health leaders, and researchers sent this letter with information about the 1/4/6x24 Campaign...

Cover of the brief: Hepatitis C and COVID-19 Global Concerns: Sustained Financing and Expanded Access to Testing and Pangenotypic Treatments Needed to Recover the Path to Elimination

Hepatitis C and COVID-19 Global Concerns: Sustained Financing and Expanded Access to Testing and Pangenotypic Treatments Needed to Recover the Path to Elimination

February 1, 2021
Dorrit Walsh

This policy brief highlights strategies that leverage the COVID-19 response towards improving access to HCV diagnostics, treatment, and care.

Advancing Access through Market Interventions: Lessons Learned from the GeneXpert Tuberculosis Test Buy-Down

September 21, 2020
Dorrit Walsh

This policy brief examines lessons learned from the Xpert MTB/RIF TB test buy-down and provides recommendations and pro-access conditions that should be applied to R&D funding, buy-down, and other market intervention agreements for COVID-19 diagnostics.

Demanding a Higher Standard of TB Care

September 2, 2020
Dorrit Walsh

In these two webinars, Treatment Action Group (TAG) launched the two latest additions to our series of materials designed for community leaders, An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis and An Activist’s Guide to Tuberculosis Diagnostic Tools.

Cover image of publication, An Activist's Guide to TB Diagnostic Tools

An Activist’s Guide to Tuberculosis Diagnostic Tools

July 28, 2020
Dorrit Walsh

Our publication, An Activist’s Guide to Tuberculosis Diagnostic Tools, details the latest WHO recommendations, the array of available TB diagnostic tools, and how these tools should be optimally used in country programs, including to support TB screening and diagnosis among special populations such as children, people with extrapulmonary TB, and people living with HIV/AIDS (PLWHA).

Open Letter to the Diagnostics Supply Consortium

April 24, 2020
Dorrit Walsh

On 24 April 2020, advocates sent an open letter to the Diagnostics Supply Consortium calling for a higher level of global coordination, transparency, and accountability to ensure sustainable and equitable access to molecular diagnostic testing for COVID-19...

Treatment Action Group Statement on the High Price of Cepheid’s Xpert Test for COVID-19

March 27, 2020
Dorrit Walsh

Cepheid is profiteering during a pandemic, with dangerous consequences for countries with vulnerable populations and health systems. New York, March 27, 2020 — Treatment Action Group calls for Cepheid to immediately lower to US$ 5 the developing country price of…

Science-Based Activism to End Epidemics, from AIDS to COVID-19

March 25, 2020
Dorrit Walsh

We hope you’re staying safe and sanitized during this difficult time! Here at TAG, we’re fortunate to be able to safely work from home, and advance the fight against HIV, tuberculosis, and hepatitis C — and now against COVID-19.

Responding to Difficult-to-Treat HCV Subtypes Prevalent in Sub-Saharan Africa

February 17, 2020
Dorrit Walsh

An issue brief that discusses the recent discovery of HCV subtypes that show resistance to direct-acting antiretroviral (DAA) regimens that are responsive to treatments in people expressing the 1a/1b subtype.